PF-Atlas › Clinical Trials › NCT03066453
Evaluation of Short Antibiotic Combination Courses Followed by Aerosols in Cystic Fibrosis
Tobi Inhalant Product · Phase 3
Registry ID
NCT03066453
Phase
Phase 3
Status
Terminated
Drug / intervention
Tobi Inhalant Product
Sponsor
University Hospital, Lille
Start
2017-06-13
Enrollment
23
Locations
7
About this trial
The aim of this study is to investigate the efficacy of antibiotic therapy with any antibiotic (IV) and IV (Nebcin®) tobramycin for 5 days followed by Solution for nebuliser inhalation (Tobi®) for 9 days and antibiotic cures using 14 days of tobramycin IV. In the case of positive results, the reduction of the duration of IV treatment of tobramycin from 14 days to 5 days would limit the risk of toxicity.
Explore related
Medical disclaimer. This page summarizes public trial data for NCT03066453 for information only. It is not medical advice, an endorsement, or an offer to enroll. Confirm details on ClinicalTrials.gov and with a qualified physician.